1NE Stock Overview
A clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Verrica Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.66 |
| 52 Week High | US$8.72 |
| 52 Week Low | US$0.58 |
| Beta | 1.4 |
| 1 Month Change | -29.34% |
| 3 Month Change | -57.53% |
| 1 Year Change | -88.26% |
| 3 Year Change | -91.98% |
| 5 Year Change | -95.30% |
| Change since IPO | -96.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1NE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.7% | -2.2% | -2.0% |
| 1Y | -88.3% | -15.8% | 6.8% |
Return vs Industry: 1NE underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 1NE underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 1NE volatility | |
|---|---|
| 1NE Average Weekly Movement | 24.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1NE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1NE's weekly volatility has increased from 16% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 100 | Jayson Rieger | www.verrica.com |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
Verrica Pharmaceuticals Inc. Fundamentals Summary
| 1NE fundamental statistics | |
|---|---|
| Market cap | €60.41m |
| Earnings (TTM) | -€81.67m |
| Revenue (TTM) | €8.85m |
6.9x
P/S Ratio-0.7x
P/E RatioIs 1NE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1NE income statement (TTM) | |
|---|---|
| Revenue | US$9.21m |
| Cost of Revenue | US$22.68m |
| Gross Profit | -US$13.47m |
| Other Expenses | US$71.52m |
| Earnings | -US$84.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -146.28% |
| Net Profit Margin | -922.81% |
| Debt/Equity Ratio | -127.2% |
How did 1NE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:16 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Verrica Pharmaceuticals Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Oren Livnat | H.C. Wainwright & Co. |